Drug Approval | April 21, 2022
Boehringer Ingelheim launches RenuTend to heal ligament injuries in horses
Targeted action improves quality of healing of tendon and suspensory ligament injuries in horses
Targeted action improves quality of healing of tendon and suspensory ligament injuries in horses
India-Sweden Healthcare Innovation Centre in collaboration with AIIMS Jodhpur and AstraZeneca India launches an e-learning Upskilling Program in Diabetes Management for nurses
These courses are for pre-selected candidates who have completed their MBBS with an additional 2 years of surgical experience training
A new course at the Azrieli Faculty of Medicine will focus on tissue regeneration and 3D printing for therapeutic needs
12-week certificate course commences on March 10th 2022
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Subscribe To Our Newsletter & Stay Updated
